Featured

Agonist anti-CD40 converts Tregs from foes to friends

Recent investigations into the use of agonist anti-CD40 for cancer immunotherapy have shown that this treatment not only enhances APC functions, but also reduces regulatory T cells (Tregs) within the tumor microenvironment (TME), despite a lack of...

Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs

Li et al. engineered an oncolytic vaccinia virus that expressed truncated CD19 and EGFRvIII on GBM cells (OVDual) and a bispecific CD19/EGFRvIII CAR-T (BiCAR-T). BiCAR-T cells effectively targeted OVD...

In vivo CAR T cell generation using retargeted and functionalized lentiviral vectors with reduced immunogenicity

Measles virus (MeV) recognizes and fuses with target cells via hemagglutinin (H) and fusion (F) proteins, respectively. To achieve T cell-specific transduction, Ibrahim et al. produced a lentivirus (L...

Mitochondrial metabolism and signaling direct dendritic cell function in antitumor immunity

You and Kim et al. identified discrete mitochondrial states in intratumoral cDC1s, wherein cDC1s with polarized mitochondria more effectively primed CD8+ T cells than depolarized cDC1s. OPA1 regulated...

PD-1 antibody-bound progenitor-exhausted CD8+ T cells in lymph nodes boost PD-1-blockade anti-tumor immunity in gastrointestinal cancer

Utilizing scRNA/TCRseq, CITEseq, and a novel assay for cell-bound anti-PD-1 to study the dynamics of T cells targeted by anti-PD-1, Nose and Yasumizu et al. first found that abundance of progenitor-ex...

See all for this week

Previous Digests

Stopping the shredder to unlock a novel source of valuable neoantigens

April 15, 2026

Inadequate neoantigen presentation in cancer hampers the endogenous antitumor immune response and the efficacy of immunotherapy. One mechanism that limits the production of immune-targetable antigens is nonsense-mediated mRNA decay (NMD). NMD degrades transcripts with premature termination codons (PTCs), eliminating...

KEYSTONE SYMPOSIA: Cancer Immunotherapy: Basic Mechanisms Informing Clinical Application

April 8, 2026

The ACIR team attended the Keystone Symposia on Cancer Immunotherapy: Basic Mechanisms Informing Clinical Application held on March 15-18, 2026 in Quebec, QC, Canada. This week’s extensive special feature covers select talks from the conference. We have organized the...

LNP mRNA delivery gets a metabolic boost from amino acid supplement

April 1, 2026

Notice: The article we intended to feature this week was briefly delayed in publication. We will share it with you as soon as the embargo is lifted. In the meantime, we encourage you to revisit last week's feature — it's well...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials